Patent Baristas

Today’s Washington Post features a story on Ismed’s efforts to promote a follow-on biologics approval pathway here in Washington.  The article outlines the campaign by Insmed’s chief exec, Geoffrey Allan, to give Congress a lesson in biotechnology. The sudden outpouring of educational efforts on protein structures and drug pharmacology has to do with the fact […]

Billed as the ONE AND ONLY course where you will learn how to add value to your practice by drilling into the complex nuances of pharmaceutical and biotech patent opinion writing to reveal the strategies, solutions, and tactics for successfully tackling the issues, ACI’s Intensive Course in Pharmaceutical and Biotech Patent Opinion Writing will bring […]

In a notice labeled “Clarification of Patent Regulations Currently in Effect, and Revision in Applicability Date of Provisions Relating to Patent Applications Containing Patentably Indistinct Claim,” the US Patent and Trademark Office (USPTO) published a notice to “clarify” just which patent-related regulations are currently in effect. The earlier proposed changes in the Claims and Continuations […]

In a bit of shameless self-promotion, we find that the Patent Baristas were ranked (once again!) in the 2008 Edition of Chambers and Partners, a guide to the legal profession that rates attorneys and their practices based upon peer and client review. Chambers USA touts the Intellectual Property Department as known for their “exceptional” attention […]

Yali Friedman announced the new, Third Edition of Building Biotechnology, known as the definitive primer and leading textbook on the business of biotechnology is now available in its third edition.We have not read the newest edition but it promises to be better than ever. This new edition is a whopper containing 20 Chapters, 460 pages […]

The phosita® blog notes perhaps the first dismissal of a declaratory judgment action following the Supreme Court’s decision in MedImmune.  In a dispute over U.S. Pat. No. 5,247,356, a patent involving photogrammetry*, a court in Minneapolis dismissed two counts seeking declaratory judgment of non-infringement and invalidity (Case 08–cv-00816). [*Apparently, photogrammetry is the science of making […]

In a nonprecedential opinion, the U.S. Court of Appeals for the Federal Circuit gave the thumbs up to a district court decision that Plaintiff-Appellant Novo Nordisk A/S wasn’t getting a preliminary injunction out of Sanofi-Aventis after alleging that Sanofi’s SoloStar product infringed claims of Novo’s U.S. Patent No. 7,241,278.  Novo Nordisk A/S v. Sanofi-Aventis (08-1225). […]

The U.S. Court of Appeals for the Federal Circuit ruled that the manufacture, marketing, or sale of a medical device, which is used in the development of FDA regulatory submissions, but is not itself subject to the FDA premarket approval process, is not entitled to the protection of the Hatch-Waxman Act section 271(e)(1) safe harbor […]